ADHD症状に関連する鑑別診断におけるQbMobileの性能に関する検討
ADHD症状に関連する鑑別診断におけるQbMobileの性能に関する検討。
The purpose of this study is to evaluate QbMobile's ability to collect objective data to identify specific symptom profiles in differential diagnoses (ASD, MDD, Bipolar Disorder and Anxiety Disorder) that are common with ADHD.
調査の概要
状態
詳細な説明
This study aims to evaluate the performance of QbMobile in children, adolescents, and adults assessed for and diagnosed with ASD (Autism Spectrum Disorder, MDD (Major Depressive Disorder), Bipolar Disorder, or Anxiety Disorder, or has a prior diagnosis of one of the included disorders but is not currently receiving treatment. Participants will complete the 10-minute QbMobile test on their personal device during a scheduled clinical visit. They will then repeat the test remotely the following day at the same time as the previous test +/-3 hours. Participants will be asked to complete QbMobile prior to initiating any treatment.
Note on Outcome Measures Presentation:
The IRB-approved protocol defines endpoints broadly (e.g., identification of QbMobile domain profiles, classification accuracy, variability, and exploratory analyses). To comply with ClinicalTrials.gov requirements that each outcome measure represent a single assessment with a single unit of measure, these endpoints are operationalized into separate outcome measures corresponding to individual QbMobile metrics (domain SD-scores, Total Score [0-100], accuracy percentages, variability estimates).
This operationalization does not introduce new scientific endpoints or alter study objectives, design, or analyses. It ensures clarity and compliance for registry reporting while maintaining alignment with the approved protocol.
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
Florida
-
Miami、Florida、アメリカ、33133
- CCM Clinical Research Group
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Potential study participants who meet the eligibility criteria will be identified through referrals and recruitment efforts at the participating study sites.
説明
Inclusion Criteria:
- Provide written informed consent (including parent/legal guardians consent when this is required for individuals under 18 years old and assent as is required based on the age of participant) for QbMobile;
- Aged > 6 years and < 60 years old;
- Referred for an initial assessment for ASD, MDD, Bipolar Disorder or Anxiety Disorder (Separation Anxiety Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)) or has a prior diagnosis of one of the included disorders but is not currently receiving treatment;
- Meets DSM-5 or ICD-11 criteria for a primary diagnosis of ASD, MDD, Bipolar Disorder or Anxiety Disorder per sites standard clinical procedures;
- Have adequate sensory and physical ability to complete QbMobile;
- Possess or have access to an iPhone model that supports QbMobile.
Exclusion Criteria:
- Intellectual disability designated by IQ<70;
- Has a DSM-5 or ICD-11 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, psychotic disorder due to another medical condition, PTSD, antisocial personality disorder, or borderline personality disorder;
- Has a primary diagnosis of ADHD (combined, inattentive, or hyperactivity/impulsive presentation);
- Has a concurrent medical diagnosis that could significantly affect test performance such as brain injuries, Parkinson's disease, current epilepsy or active seizures, amyotrophic lateral sclerosis (ALS), multiple sclerosis, dementias (e.g. vascular dementia, Alzheimer disease, etc);
- Has other conditions that could affect test performance (migraine or other types of severe headache, chronic or acute pain);
- Use of prescription medications (e.g., anxiolytics, sedative medications) taken on the day before completing QbMobile that could significantly affect performance;
- Substance use (e.g., alcohol, drugs) that may affect performance on the day of the tests.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_ONLY
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
ASD
Eligible participants being referred for their initial assessment or have a diagnosis of ASD but currently not receiving treatment who are attending a clinic visit at study sites will be approached by a clinic research staff about the study or contacted prior to their appointment. |
Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study. |
|
Bipolar disorder
Eligible participants being referred for their initial assessment or have a diagnosis of Bipolar Disorder but currently not receiving treatment who are attending a clinic visit at study sites will be approached by a clinic research staff about the study or contacted prior to their appointment. |
Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study. |
|
MDD
Eligible participants being referred for their initial assessment or have a diagnosis of MDD but currently not receiving treatment who are attending a clinic visit at study sites will be approached by a clinic research staff about the study or contacted prior to their appointment. |
Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study. |
|
Separation Anxiety Disorder
Eligible participants being referred for their initial assessment or have a diagnosis of Separation Anxiety Disorder but currently not receiving treatment who are attending a clinic visit at study sites will be approached by a clinic research staff about the study or contacted prior to their appointment. |
Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study. |
|
Social Anxiety Disorder
Eligible participants being referred for their initial assessment or have a diagnosis of Social Anxiety Disorder but currently not receiving treatment who are attending a clinic visit at study sites will be approached by a clinic research staff about the study or contacted prior to their appointment. |
Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study. |
|
Generalized Anxiety Disorder
Eligible participants being referred for their initial assessment or have a diagnosis of Generalized Anxiety Disorder but currently not receiving treatment who are attending a clinic visit at study sites will be approached by a clinic research staff about the study or contacted prior to their appointment. |
Participants will complete two non-invasive, 10-minute digital tests using the QbMobile Investigational Device-one at the clinic and one at home the following day. The tests objectively measure cognitive performance and activity levels and will not influence clinical diagnosis or treatment in this study. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Identification of QbMobile Domain Profiles Using SD-Scores and Total Score (0-100)
時間枠:Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
QbMobile is a software application that measures cognitive performance and activity levels, including attention, impulsivity, activity, and movement patterns. The study will identify statistically distinct QbMobile domain profiles for each diagnostic group (ASD, MDD, Bipolar Disorder, Anxiety Disorder) using domain SD-scores and the QbMobile Total Score (0-100). (Component metrics are listed as secondary outcomes to meet single-measure reporting requirements.) |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
QbMobile Domain SD-Scores (Attention, Impulsivity, Activity, Movement) - Group Differences
時間枠:Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
QbMobile is a software application that measures cognitive performance and activity levels. Domain scores will be analyzed as SD-scores to assess differences among diagnostic groups (ASD, MDD, Bipolar Disorder, Anxiety Disorder). |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
|
QbMobile Total Score (0-100) - Group Differences
時間枠:Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
QbMobile is a software application that measures cognitive performance and activity levels. The Total Score (0-100; higher values indicate greater likelihood of ADHD symptomatology) will be compared across diagnostic groups to assess differences. |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
|
Classification Accuracy Using QbMobile Domain SD-Scores
時間枠:Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
QbMobile is a software application that measures cognitive performance and activity levels. Classification accuracy among diagnostic groups will be evaluated using domain SD-scores; metrics will include sensitivity, specificity, and predictive values. |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2)
|
|
Classification Accuracy Using QbMobile Total Score (0-100)
時間枠:QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2)
|
QbMobile is a software application that measures cognitive performance and activity levels. Classification accuracy among diagnostic groups will be evaluated using the Total Score; metrics will include sensitivity, specificity, and predictive values based on prespecified thresholds. |
QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2)
|
|
Comparison of QbMobile Domain SD-Scores with Normative Dataset
時間枠:Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).
|
QbMobile is a software application that measures cognitive performance and activity levels. Domain SD-scores will be compared with the age- and sex-adjusted normative dataset to identify differences between diagnostic groups and normative patterns. |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).
|
|
Comparison of QbMobile Total Score (0-100) with Normative Distribution
時間枠:Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).
|
QbMobile is a software application that measures cognitive performance and activity levels. Total Scores will be compared with the normative distribution to identify deviations from expected values. |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).
|
|
Variability in Differentiation Using QbMobile Domain SD-Scores
時間枠:Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).
|
QbMobile is a software application that measures cognitive performance and activity levels. Variability in group differentiation will be assessed using domain SD-scores (e.g., confidence intervals and variance estimates across repeated measures). |
Two QbMobile tests: at the clinic (Visit 1) and remotely the following day (Visit 2).
|
|
Variability in Differentiation Using QbMobile Total Score (0-100)
時間枠:QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2).
|
QbMobile is a software application that measures cognitive performance and activity levels. Variability will be assessed using Total Scores (e.g., confidence intervals and variance estimates across repeated measures). |
QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2).
|
|
Exploratory Analysis of Additional QbMobile Domain Parameters (SD-Based)
時間枠:QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2).
|
Consistent with the protocol statement that "all data collected from QbMobile during this study will be available to explore additional domain parameters," exploratory analyses will examine QbMobile domain data using SD-based metrics to identify additional parameters for further analysis. |
QbMobile completed at Visit 1 (Day 1) and Visit 2 (Day 2).
|
|
Exploratory Analysis of Additional QbMobile Parameters from Total Score and Raw Performance Data
時間枠:Visit 1 (clinic) and Visit 2 (remote, next day).
|
Consistent with the protocol statement that "all data collected from QbMobile… will be available to explore additional domain parameters," exploratory analyses will use the QbMobile Total Score (0-100) and raw performance data (e.g., response time, error counts, movement traces) to identify additional parameters for further analysis. |
Visit 1 (clinic) and Visit 2 (remote, next day).
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Pro00090568 QB25-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Due to the nature of the research, limited access to supporting data may be granted upon reasonable request under confidentiality agreements from the corresponding sponsor.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。